Cory Wohlbach is Global Vice President, Biosimilars Regulatory Affairs at Teva Pharmaceutical Industries Ltd. In this role, Cory leads Teva’s regulatory strategy for biosimilar medicines. Before leading the biosimilars regulatory affairs team, Cory spent over eight years in regulatory affairs at Teva developing and gaining approval of complex generic drug products, generic drug-device combination products, sterile injectable generic drugs and biologics/biosimilars. Prior to Teva, Cory also held regulatory affairs positions at MedImmune and Sanofi Pasteur. Cory holds a B.S. in Biology from Muhlenberg College in Pennsylvania.